1 Min Read
June 26 (Reuters) - Catalyst Biosciences Inc
* Catalyst Biosciences announces achievement of stable normal factor IX blood levels in a preclinical subcutaneous dosing model Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.